Inhibition of testosterone metabolism by medrogestone in rat ventral prostate in vivo and in vitro.
Medrogestone (MDG), viz., 6,17-dimethyl-4,6-pregnadiene-3,20-dione (Colprone), a synthetic compound with progestational and antiandrogenic properties was studied for its effect on the conversion of testosterone (T) to 5 alpha-dihydrotestosterone (DHT) and 5 alpha-androstane-3 alpha(beta)-17 beta-diol (Adiol) by ventral prostatic preparations of the rat. MDG, 20 mg/kg b.w./day s.c. for 14 days, inhibited the conversion of T to DHT by ventral prostatic homogenates and cytoplasm and at the same dose and route, but for 28 days, it reduced the conversion of T to DHT by ventral prostatic nuclei and T to Adiol by ventral prostatic cytoplasm and nuclei. MDG, from 1 X 10(-4) to 1 X 0(-5) M final concentration in vitro, induced dose-dependent decreases in the conversions of T to DHT and Adiol by ventral prostatic nuclei.
D015113:Androstane-3,17-diol / Q000378:metabolism; D000818:Animals; D013196:Dihydrotestosterone / Q000378:metabolism; D008297:Male; D008524:Medrogestone / Q000494:pharmacology*; D011245:Pregnadienes / Q000494:pharmacology*; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D013739:Testosterone / Q000378:metabolism*
D011245:Pregnadienes; D008524:Medrogestone; D013196:Dihydrotestosterone; D015113:Androstane-3,17-diol; D013739:Testosterone